Benitec Biopharma switches auditor to Ernst & Young from Baker Tilly
Bitget2026/09/24 20:39- Benitec Biopharma replaced auditor Baker Tilly with Ernst & Young for the fiscal year ending June 30, 2027.
- Audit committee dismissed Baker Tilly on Sept. 18, 2026; Baker Tilly was notified on Sept. 21, 2026.
- Baker Tilly’s audit opinions for fiscal 2026 and 2025 were unqualified, with no going-concern or scope modifications.
- No accounting or auditing disputes were reported with Baker Tilly through Sept. 21, 2026.
- Only reportable issue cited was a 2025 material weakness in share-based compensation controls, remediated by June 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
